HK1223396A1 - 用於治療或預防胰功能異常的方法 - Google Patents

用於治療或預防胰功能異常的方法

Info

Publication number: HK1223396A1
Authority: HK; Hong Kong
Prior art keywords: treating; preventing; pancreatic dysfunction; dysfunction; pancreatic
Prior art date: 2008-11-20

Application number

HK16111604.7A

Other languages

English (en)

Inventor

Itescu Silviu

Krishnan Ravi

Original Assignee

Mesoblast Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-20

Filing date

2016-10-05

Publication date

2017-07-28

2016-10-05 Application filed by Mesoblast Inc filed Critical Mesoblast Inc

2017-07-28 Publication of HK1223396A1 publication Critical patent/HK1223396A1/zh

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/62—Insulins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Immunology (AREA)
Zoology (AREA)
Hematology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Developmental Biology & Embryology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Endocrinology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Obesity (AREA)
Reproductive Health (AREA)

HK16111604.7A 2008-11-20 2016-10-05 用於治療或預防胰功能異常的方法 HK1223396A1 (zh)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US19979608P	2008-11-20	2008-11-20

Publications (1)

Publication Number	Publication Date
HK1223396A1 true HK1223396A1 (zh)	2017-07-28

Family

ID=42197754

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK14110752A HK1197186A1 (zh)	2008-11-20	2014-10-27	用於治療胰功能異常的方法
HK16111604.7A HK1223396A1 (zh)	2008-11-20	2016-10-05	用於治療或預防胰功能異常的方法

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HK14110752A HK1197186A1 (zh)	2008-11-20	2014-10-27	用於治療胰功能異常的方法

Country Status (11)

Country	Link
US (3)	US8894972B2 (zh)
EP (2)	EP2350266B1 (zh)
JP (6)	JP5891034B2 (zh)
KR (2)	KR101832497B1 (zh)
CN (3)	CN104546912B (zh)
AU (1)	AU2009317874B2 (zh)
CA (1)	CA2744228C (zh)
DK (1)	DK2350266T3 (zh)
ES (2)	ES2550795T3 (zh)
HK (2)	HK1197186A1 (zh)
WO (1)	WO2010057260A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2550795T3 (es) *	2008-11-20	2015-11-12	Mesoblast, Inc.	Método para tratar o prevenir una disfunción pancreática
JP5984396B2 (ja)	2009-03-05	2016-09-06	プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ	分泌されたａＰ２およびこれを阻害する方法
EP2593115A4 (en)	2010-07-02	2013-12-04	Mesoblast Inc	TREATMENT OF T-CELL-MEDIATED IMMUNE TROUBLESHOOTING
SG194930A1 (en)	2011-05-19	2013-12-30	Mesoblast Inc	Methods for treating obesity and/or metabolic syndrome
AU2012262675B2 (en) *	2011-06-03	2016-05-19	Mesoblast, Inc	Methods of treating or preventing neurological diseases
EP2729155B1 (en) *	2011-07-04	2019-10-30	Mesoblast, Inc.	Methods of treating or preventing rheumatic disease
PL2729562T3 (pl)	2011-07-06	2018-10-31	Cell Therapy Limited	Komórki progenitorowe pochodzenia mezodermalnego
CN104098682B (zh) *	2013-04-03	2018-01-02	苏州偲聚生物材料有限公司	多肽、包含该多肽的检测器件和检测试剂盒
CN105358163B (zh) *	2012-12-12	2020-09-11	麦瑟布莱斯特公司	内皮功能障碍和炎症的疾病的治疗
US20140314872A1 (en) *	2013-04-22	2014-10-23	Hans Klingemann	Methods of Use of Culture Supernatant Obtained from Mesenchymal Stem Cells from Dogs and Cats for Treatment of Organ Dysfunction
CN104714021B (zh) *	2013-12-12	2016-05-25	张曼	尿液凝血酶原蛋白在2型糖尿病合并冠心病中的应用
CN107667116A (zh)	2015-04-30	2018-02-06	哈佛学院院长及董事	治疗代谢病症的抗‑ap2 抗体及抗原结合剂
WO2018005551A1 (en) *	2016-06-27	2018-01-04	President And Fellows Of Harvard College	Compounds useful to treat metabolic disorders
EP3634479A4 (en)	2017-06-09	2021-04-14	President and Fellows of Harvard College	PROCESS FOR IDENTIFYING COMPOUNDS USEFUL FOR TREATING DEREGULATED LIPOGENESIS, DIABETES AND OTHER RELATED DISORDERS
CN110959579A (zh) *	2019-11-14	2020-04-07	顾隽	患者来源的淋巴瘤免疫缺陷小鼠移植瘤模型的构建方法及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
WO1992001070A1 (en)	1990-07-09	1992-01-23	The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce	High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
AU663725B2 (en)	1991-08-20	1995-10-19	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Adenovirus mediated transfer of genes to the gastrointestinal tract
AU2003901668A0 (en)	2003-03-28	2003-05-01	Medvet Science Pty. Ltd.	Non-haemopoietic precursor cells
AUPQ147799A0 (en)	1999-07-07	1999-07-29	Medvet Science Pty. Ltd.	Mesenchymal precursor cell
DE19939781C2 (de)	1999-08-21	2003-06-18	Schott Glas	Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken
US20040063204A1 (en) *	2002-08-14	2004-04-01	Lijun Yang	Bone marrow cell differentiation
ATE493492T1 (de) *	2003-11-04	2011-01-15	Biomaster Inc	Verfahren und system zur herstellung von stammzellen aus fettgewebe
CN101506355B (zh)	2004-09-24	2012-06-27	成血管细胞系统公司	多能扩增间充质前体细胞子代（memp）及其应用
WO2006108229A1 (en) *	2005-04-12	2006-10-19	Angioblast Systems, Inc.	Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
GB0514785D0 (en) *	2005-07-19	2005-08-24	Innovia Films Ltd	Sealed ream wrap package and films suitable for forming such packages
EP2023943A2 (en) *	2006-04-28	2009-02-18	Tulane University Health Sciences Center	Methods for treating diabetes
US20100247491A1 (en) *	2007-02-01	2010-09-30	Christof Westenfelder	Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure
ES2550795T3 (es)	2008-11-20	2015-11-12	Mesoblast, Inc.	Método para tratar o prevenir una disfunción pancreática
US9405700B2 (en)	2010-11-04	2016-08-02	Sonics, Inc.	Methods and apparatus for virtualization in an integrated circuit

2009
- 2009-11-19 ES ES09827049.9T patent/ES2550795T3/es active Active
- 2009-11-19 CN CN201410727242.0A patent/CN104546912B/zh active Active
- 2009-11-19 KR KR1020117012519A patent/KR101832497B1/ko active IP Right Grant
- 2009-11-19 EP EP09827049.9A patent/EP2350266B1/en active Active
- 2009-11-19 CN CN200980155054.2A patent/CN102307992B/zh active Active
- 2009-11-19 US US13/129,180 patent/US8894972B2/en active Active
- 2009-11-19 JP JP2011536703A patent/JP5891034B2/ja active Active
- 2009-11-19 KR KR1020187004814A patent/KR102011609B1/ko active IP Right Grant
- 2009-11-19 CN CN201310652234.XA patent/CN103800370B/zh active Active
- 2009-11-19 EP EP15178550.8A patent/EP3002329B1/en active Active
- 2009-11-19 AU AU2009317874A patent/AU2009317874B2/en active Active
- 2009-11-19 CA CA2744228A patent/CA2744228C/en active Active
- 2009-11-19 ES ES15178550.8T patent/ES2651503T3/es active Active
- 2009-11-19 DK DK09827049.9T patent/DK2350266T3/en active
- 2009-11-19 WO PCT/AU2009/001511 patent/WO2010057260A1/en active Application Filing
2014
- 2014-10-27 HK HK14110752A patent/HK1197186A1/zh unknown
- 2014-11-07 US US14/535,827 patent/US9480713B2/en active Active
2015
- 2015-06-02 JP JP2015111995A patent/JP6499016B2/ja active Active
2016
- 2016-10-05 HK HK16111604.7A patent/HK1223396A1/zh unknown
- 2016-10-27 US US15/336,234 patent/US9968640B2/en active Active
2017
- 2017-06-07 JP JP2017112578A patent/JP2017214384A/ja not_active Withdrawn
2019
- 2019-09-06 JP JP2019162845A patent/JP7051770B2/ja active Active
2021
- 2021-10-29 JP JP2021177234A patent/JP2022031662A/ja not_active Withdrawn
2023
- 2023-05-26 JP JP2023086994A patent/JP2023116536A/ja active Pending

Also Published As

Publication number	Publication date
JP2015205894A (ja)	2015-11-19
KR101832497B1 (ko)	2018-02-26
AU2009317874B2 (en)	2016-04-21
JP2022031662A (ja)	2022-02-22
JP7051770B2 (ja)	2022-04-11
JP2020011972A (ja)	2020-01-23
US20170042945A1 (en)	2017-02-16
AU2009317874A1 (en)	2010-05-27
CA2744228A1 (en)	2010-05-27
CA2744228C (en)	2018-06-19
EP3002329A1 (en)	2016-04-06
JP2023116536A (ja)	2023-08-22
EP2350266A4 (en)	2013-03-06
WO2010057260A1 (en)	2010-05-27
HK1197186A1 (zh)	2015-01-09
ES2651503T3 (es)	2018-01-26
CN103800370A (zh)	2014-05-21
US8894972B2 (en)	2014-11-25
US20110243902A1 (en)	2011-10-06
CN104546912A (zh)	2015-04-29
CN102307992A (zh)	2012-01-04
US9480713B2 (en)	2016-11-01
JP5891034B2 (ja)	2016-03-22
US9968640B2 (en)	2018-05-15
DK2350266T3 (en)	2015-11-02
JP6499016B2 (ja)	2019-04-10
CN102307992B (zh)	2015-01-07
KR20180021230A (ko)	2018-02-28
CN104546912B (zh)	2019-11-08
JP2012509283A (ja)	2012-04-19
EP3002329B1 (en)	2017-08-16
KR102011609B1 (ko)	2019-08-16
EP2350266B1 (en)	2015-07-29
JP2017214384A (ja)	2017-12-07
US20150064148A1 (en)	2015-03-05
CN103800370B (zh)	2017-10-24
KR20110095875A (ko)	2011-08-25
EP2350266A1 (en)	2011-08-03
ES2550795T3 (es)	2015-11-12

Publication	Publication Date	Title
HK1223396A1 (zh)	2017-07-28	用於治療或預防胰功能異常的方法
IL257418A (en)	2018-04-30	Methods for treating addiction
EP2137280A4 (en)	2010-09-08	METHOD FOR TREATING A FRACTURED FORMATION
GB2456111B (en)	2011-09-21	Method for treating a subterranean formation
EP2019675A4 (en)	2011-03-02	METHODS FOR TREATING OR PREVENTING NEOPLASIA
EP2134806A4 (en)	2011-08-03	METHOD FOR TREATING A CARBON HYDROGEN INFORMATION
EP2188299A4 (en)	2012-12-12	METHOD FOR TREATING DIABETES
EP2139933A4 (en)	2012-01-11	METHOD FOR TREATING FORMATION WITH A SOLVENT
PL2260150T3 (pl)	2015-10-30	Sposób zapobiegania zwaliskom
GB0813278D0 (en)	2008-08-27	Method for inhibiting corrosion
EP1987110A4 (en)	2009-11-11	METHOD OF SUBSTRATE TREATMENT
PL2301893T3 (pl)	2018-10-31	Sposób oczyszczania ścieku
EP2299822A4 (en)	2011-10-26	METHOD FOR TREATING NEURODEGENERATIVE DYSFUNCTION
PT2096102E (pt)	2014-05-27	Processo para a produção de metileno-difenil-diisocianatos
EP2236467A4 (en)	2012-10-17	PROCESS FOR SLUDGE DRYING
AP2010005522A0 (en)	2010-12-31	A method of treating a sulphide mineral.
PL2376597T3 (pl)	2014-10-31	Proces obróbki odpadów
PL2441462T3 (pl)	2020-01-31	Sposób leczenia cukrzycy typu I
ZA200904282B (en)	2010-08-25	Method for manufacturing an austenitic steel object
PT2393758E (pt)	2013-03-07	Processo de tratamento de águas residuais
EP2231150A4 (en)	2011-06-22	METHOD FOR SEARCH TREATMENT WITH CROSS-COMPOSITE COMPOSITIONS
ZA200903900B (en)	2010-08-25	Method for treating ligno-cellulosic materials
EP2296461A4 (en)	2013-10-23	METHODS OF TREATING ARTHROPODS
GB2453912B (en)	2011-12-28	Method for treating spent pot liner
PT2509599E (pt)	2014-10-15	Processo para o tratamento de cancro pancreático